Company / EPS (Diluted)
Abbott Laboratories EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$3.26
FY2025
5-year range
$2.06 / $3.94
FY2021-FY2025
Trend
-16.6%
vs FY2024
Sector context
#45 of 159
Health Care
What the data says
At $3.26, Abbott Laboratories's eps (diluted) ranks #45 of 159 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $0.27 in FY2019 to $3.94 in FY2023.
Based on SEC 10-K filings.
3.26 in FY2025 with a 5-year CAGR of +19.6%.
Declined from $3.94 to $3.26 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +9.3%
- 5-Year CAGR
- +19.6%
- 10-Year CAGR
- -
Sector benchmark
#45 of 159 in Health CareTop 28% of 159This company $3.26 Sector average $1.67
▼
+95.4% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 16.6% year-over-year.
- Ranks #45 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.26 | -16.6% |
| FY2024 | $3.91 | -0.8% |
| FY2023 | $3.94 | +57.6% |
| FY2022 | $2.50 | +21.4% |
| FY2021 | $2.06 | +54.9% |
| FY2020 | $1.33 | +392.6% |
| FY2019 | $0.27 | -71.3% |
| FY2018 | $0.94 | -67.8% |
| FY2017 | $2.92 | +96.0% |
| FY2016 | $1.49 | -8.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026